BERLIN, Germany, June 11, 2024 – Tacalyx, a privately held biotech company focused on developing novel anti-TACA (Tumor Associated Carbohydrate Antigens) cancer therapies, announces the extension of its seed financing to over €14 M. This extension…
University ranks ninety-seventh in the world. According to this year’s QS World University Rankings, Freie Universität Berlin is among the top four universities in Germany. The rankings are published annually by higher education consulting firm…
• Regenerative Medicine Advanced Therapy (RMAT) designation follows phase I clinical trial results demonstrating that bemdaneprocel is well tolerated with no major safety issues through 18 months
• Bemdaneprocel is the most clinically advanced…
Blood stem cells from healthy people carry major chromosomal alterations, a study in “Nature Genetics” by researchers at the Max Delbrück Center and the European Molecular Biology Laboratory finds. The discovery suggests that we are all genetic…
Application starts on June 3, 2024 and ends on November 22, 2024
Deadline: June 7, 2024
Join the BARDA VITAL Prize (BVP) Challenge for Breakthrough Vaccines and Therapeutics
Eckert & Ziegler SE (ISIN DE0005659700) was honored with the “Best Managed Companies Award” at an award ceremony in Frankfurt am Main on May 23, 2024. With this award, Deloitte Private, UBS, Frankfurter Allgemeine Zeitung and the Federation of German…
Captain T Cell, a spin-off from the Max Delbrück Center, raised €8.5 million in startup funding. The startup focuses on developing T cells to target solid tumors. The funds are intended to move a new generation of T cell therapies towards the clinic.
Preeclampsia is one of the most common pregnancy-related complications. Florian Herse of the Max Delbrück Center and Martin Gauster of the Medical University of Graz are studying the role that Hofbauer cells play in the disorder. They have been…
Join us at this year's "Current Topics in Bioinformatics" symposium, where we'll explore single cell- and spatially resolved technologies.
